Skip to main content
. 2001 Feb;132(3):722–728. doi: 10.1038/sj.bjp.0703762

Figure 5.

Figure 5

(A) Distribution of BODIPY-Ivermectin in control capillaries and capillaries incubated with substrates and blockers of p-glycoprotein (10 μM PSC-833, 10 μM Cyclosporin A, 50 μM Verapamil). Lumenal, but not cellular fluorescence is decreased (means±s.d.; n=10). (B) Distribution of the Pgp substrate BODIPY-Verapamil in the absence and in the presence of unlabelled Ivermectin. Lumenal fluorescence is significantly decreased (means±s.d; n=10). *Significantly different from control value (α<0.05).